for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AbbVie Inc

ABBV.N

Latest Trade

92.92USD

Change

0.35(+0.38%)

Volume

1,265,501

Today's Range

92.20

 - 

93.00

52 Week Range

62.55

 - 

101.27

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
92.57
Open
92.72
Volume
1,265,501
3M AVG Volume
185.61
Today's High
93.00
Today's Low
92.20
52 Week High
101.27
52 Week Low
62.55
Shares Out (MIL)
1,764.83
Market Cap (MIL)
163,988.30
Forward P/E
9.00
Dividend (Yield %)
5.08

Next Event

Q3 2020 Abbvie Inc Earnings Release

Latest Developments

More

Voyager Therapeutics Provides Update On AbbVie Vectorized Antibody Collaborations

Abbvie Posts Qtrly Loss Per Share $0.46

Abbvie Says By June-End Total Business Recovered To More Than 90% Of Pre-COVID Levels - Conf Call

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry

Biotechnology & Drugs

Contact Info

1 N Waukegan Rd

NORTH CHICAGO, IL

60064-1802

United States

+1.847.9327900

https://www.abbvie.com/

Executive Leadership

Richard A. Gonzalez

Chairman of the Board, Chief Executive Officer

Michael E. Severino

President, Vice Chairman

Carlos Alban

Vice Chairman, Chief Commercial Officer

Laura J. Schumacher

Vice Chairman, External Affairs and Chief Legal Officer

Robert A. Michael

Chief Financial Officer, Senior Vice President

Key Stats

1.94 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

28.2K

2018

32.7K

2019

33.3K

2020(E)

45.6K
EPS (USD)

2017

5.600

2018

7.910

2019

8.940

2020(E)

10.456
Price To Earnings (TTM)
20.44
Price To Sales (TTM)
4.53
Price To Book (MRQ)
11.15
Price To Cash Flow (TTM)
16.19
Total Debt To Equity (MRQ)
594.45
LT Debt To Equity (MRQ)
557.93
Return on Investment (TTM)
8.43
Return on Equity (TTM)
6.73

Latest News

Latest News

AbbVie agrees to pay $24 million to resolve Humira California lawsuit

AbbVie Inc has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday.

AbbVie agrees to pay $24 mln to resolve Humira California lawsuit

AbbVie Inc has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday.

AbbVie's Humira powers profit beat as COVID-19 weighs on Botox sales

AbbVie Inc <ABBV.N> on Friday posted a quarterly adjusted profit above estimates as robust sales of its blockbuster arthritis treatment, Humira, helped cushion weak demand for its aesthetic drugs, including Botox, due to the COVID-19 pandemic.

BRIEF-Abbvie Says By June-End Total Business Recovered To More Than 90% Of Pre-COVID Levels - Conf Call

* ABBVIE SAYS BY THE END OF JUNE TOTAL BUSINESS RECOVERED TO MORE THAN 90% OF PRE-COVID LEVELS - CONF CALL

AbbVie reports loss as COVID-19 hits Botox sales

Drugmaker AbbVie Inc reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc deal, slumped due to the impact of the COVID-19 pandemic.

Molecular Partners's AbbVie-partnered eye drug gets FDA safety snub

Swiss drugmaker Molecular Partners has suffered a setback after the U.S. Food and Drug Administration said the company's abicipar product for a blindness-causing eye disease had an unfavorable risk-benefit profile due to inflammation.

BRIEF-Allergan, An Abbvie Company, And Molecular Partners Receive CRL From FDA On Biologics License Application For Abicipar Pegol

* ALLERGAN, AN ABBVIE COMPANY, AND MOLECULAR PARTNERS RECEIVE COMPLETE RESPONSE LETTER FROM FDA ON BIOLOGICS LICENSE APPLICATION FOR ABICIPAR PEGOL

Sosei, AbbVie sign drug discovery deal worth up to $1 bln

Japan's Sosei Group Corp will collaborate with AbbVie Inc on a drug discovery partnership that could be worth up to $1 billion.

Japan's Sosei Group signs $377 mln drug discovery deal with Abbvie

Japan's Sosei Group Corp will collaborate with Abbvie Inc on drug discovery in a deal worth up to $377 million, the companies said on Thursday.

BRIEF-Sosei Group Corp - Sosei Heptares And Abbvie Announce New Discovery Collaboration Targeting Inflammatory Diseases

* SOSEI HEPTARES AND ABBVIE ANNOUNCE NEW DISCOVERY COLLABORATION TARGETING INFLAMMATORY DISEASES

BRIEF-Imbruvica Seeks To Expand U.S. Label With Long-Term Data In Waldenström's Macroglobulinemia

* IMBRUVICA® (IBRUTINIB) SEEKS TO EXPAND U.S. LABEL WITH LONG-TERM DATA IN WALDENSTRÖM'S MACROGLOBULINEMIA (WM)

BRIEF-FDA Accepts Supplemental Biologics License Application For Botox

* FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR BOTOX® (ONABOTULINUMTOXINA) FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY

BRIEF-Assembly Biosciences -Termination Of Collaboration Agreement With Abbvie Will Be Effective 120 Days Following Notice Of Termination On October 10

* ASSEMBLY BIOSCIENCES - TERMINATION OF COLLABORATION AGREEMENT WITH ABBVIE WILL BE EFFECTIVE 120 DAYS FOLLOWING NOTICE OF TERMINATION ON OCTOBER 10

BRIEF-Assembly Biosciences Regains Worldwide Rights To Microbiome Gastrointestinal Development Programs

* ASSEMBLY BIOSCIENCES REGAINS WORLDWIDE RIGHTS TO MICROBIOME GASTROINTESTINAL DEVELOPMENT PROGRAMS

BRIEF-Abbvie Says RINVOQ Monotherapy Shows Improvement In Skin Clearance And Itch In First Phase 3 Study

* RINVOQ™ (UPADACITINIB) MONOTHERAPY SHOWS IMPROVEMENT IN SKIN CLEARANCE AND ITCH IN FIRST PHASE 3 STUDY FOR ATOPIC DERMATITIS

BRIEF-Alpine Immune Sciences And Abbvie Announce Option And License Agreement For Development And Commercialization Of ALPN-101

* ALPINE IMMUNE SCIENCES AND ABBVIE ANNOUNCE OPTION AND LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ALPN-101

BRIEF-Abbvie Sets Quarterly Cash Dividend Of $1.18Per Share

* SETS QUARTERLY CASH DIVIDEND OF $1.18PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Abbvie Says FDA Approves JUVÉDERM VOLUMA XC For Enhancement Of The Chin Region

* FDA APPROVES JUVÉDERM® VOLUMA™ XC FOR ENHANCEMENT OF THE CHIN REGION Source text for Eikon: Further company coverage:

BRIEF-Abbvie Says Venclexta/Venclyxto Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit In Phase 3 Study

* VENCLEXTA®/VENCLYXTO® (VENETOCLAX) PLUS AZACITIDINE DEMONSTRATES STATISTICALLY SIGNIFICANT OVERALL SURVIVAL BENEFIT AND IMPROVED REMISSION RATES IN TREATMENT-NAÏVE ACUTE MYELOID LEUKEMIA PATIENTS

BRIEF-Abbvie Recommends Shareholders Reject Trc Capital's "Mini-Tender" Offer

* ABBVIE RECOMMENDS SHAREHOLDERS REJECT TRC CAPITAL'S "MINI-TENDER" OFFER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up